CoreLab Partners Showcases Technologies at 47th Annual DIA Meeting
CoreLab Partners
will showcase several new technological solutions to coincide with the upcoming DIA meeting in Chicago, Illinois to be held from June 20 - 23, 2011.
“I am pleased to announce that as a part of an on-going commitment to our sponsor partners to deliver the highest possible quality through a cost effective, technologically driven process, we are positioned to launch another series of enabling solutions in both our ImagEngine SM and WebHeart platforms”, said CoreLab Partners’ President and CEO, Dr. Mike Woehle . “Our proprietary advanced imaging application, ImagEngineSM, will perform 3D and volumetric measurements while incorporating multi-planer reconstruction tools with lesion propagation which will expand our therapeutic reach and addresses the growing needs for this type of image analysis going forward,” added Woehler.
CoreLab Partners invites you to learn more about their comprehensive suite of service capabilities and new technological solutions at booth #1035 at the 47th Annual DIA meeting in Chicago, Illinois.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.
